The CBX5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from human lung adenocarcinoma A-549 cells, featuring disruption of the CBX5 gene that encodes heterochromatin protein 1?? (HP1??). This heterogeneous cell pool contains diverse knockout alleles, enabling loss-of-function studies without clonal bias. The polyclonal format is ideal for investigating HP1??-dependent chromatin biology and gene silencing in a robust lung cancer model.
The A-549 cell line, established from human lung adenocarcinoma tissue, serves as a well-characterized model of alveolar Type II pulmonary epithelium. This epithelial line is extensively used in cancer and respiratory research due to its reproducible growth, stable karyotype, and responsiveness to epigenetic and oncogenic stimuli. Its baseline expression of relevant signaling components makes it suitable for dissecting chromatin-mediated regulation.
CBX5-encoded HP1?? binds trimethylated histone H3 at lysine 9 (H3K9me3) via its chromodomain, promoting chromatin compaction and transcriptional repression. It recruits effectors like SUV39H1, DNMT1, and TRIM28/KAP1 to sustain heterochromatin. HP1?? function is modulated by p53-dependent signals and SUMOylation, and its mitotic release is triggered by Aurora B phosphorylation. Downstream, HP1?? represses cell cycle regulators such as CCND1 and CDKN1A (p21) and suppresses metastasis genes MMP2 and MMP9.
In A-549 cells, CBX5 knockout provides a direct means to explore how HP1?? loss alters heterochromatin architecture and drives epigenetic dysregulation in lung adenocarcinoma. Since A-549 is p53 wild-type, the model is apt for studying HP1??’s role in senescence and DNA damage repair. Disruption of CBX5 can derepress metastasis-related genes and perturb Wnt/??-catenin signaling via interaction with LEF1, offering insights into chromatin-dependent cancer progression mechanisms.
These knockout cells are suited for ChIP-qPCR to profile H3K9me3 redistribution, RT-qPCR and western blotting to confirm target gene derepression, and immunofluorescence for chromatin visualization. Functional assays like transwell invasion and flow cytometric cell cycle profiling can quantify altered malignancy. They also enable drug testing with HDAC or Aurora kinase inhibitors to evaluate epigenetic therapy responses. For additional information, please contact Ascent Research.
